Drug Details
| General Information of the Drug (ID: DR1920) | ||||
|---|---|---|---|---|
| Name |
BS21
|
|||
| Disease | Obesity [ICD-11: 5B81] | Investigative | [1] | |
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Orientin | Ranunculaceae | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Phosphorylation | ACACA | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CEBPA | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CHPT1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | FABP4 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | FAS | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | PPAR-gamma | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PPARGC1A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PRDM16 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PRKAA2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | SREBF1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | UCP1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | UCP2 | Molecule Info | |||
| In-vitro Model | 3T3-L1 | CVCL_0123 | Healthy | Mus musculus | ||
| Experimental
Result(s) |
BS21 plays a modulatory role in adipocytes by reducing adipogenesis and lipogenesis, increasing fat oxidation, and inducing browning. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Glucocorticoid receptor (NR3C1) | Molecule Info | [3] | |
| Phospholipase A2 inhibitory protein (PA2IP) | Molecule Info | [4] | ||
| KEGG Pathway | Neuroactive ligand-receptor interaction | Click to Show/Hide | ||
| NetPath Pathway | IL2 Signaling Pathway | Click to Show/Hide | ||
| 2 | TCR Signaling Pathway | |||
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | Click to Show/Hide | ||
| 2 | Signaling events mediated by HDAC Class II | |||
| 3 | FOXA2 and FOXA3 transcription factor networks | |||
| 4 | Glucocorticoid receptor regulatory network | |||
| 5 | Regulation of Androgen receptor activity | |||
| 6 | AP-1 transcription factor network | |||
| Reactome | BMAL1:CLOCK,NPAS2 activates circadian gene expression | Click to Show/Hide | ||
| WikiPathways | Serotonin Receptor 4/6/7 and NR3C Signaling | Click to Show/Hide | ||
| 2 | SIDS Susceptibility Pathways | |||
| 3 | Nuclear Receptors Meta-Pathway | |||
| 4 | Endoderm Differentiation | |||
| 5 | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | |||
| 6 | Adipogenesis | |||
| 7 | Circadian Clock | |||
| 8 | Nuclear Receptors | |||
